Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.

Leukemia - 1 Mar 2017

Chen Z, Shao C, Wang W, Zuo Z, Mou X, Hu S J, DiGiuseppe J A, Zu Y, Medeiros L J, Hu S

Abstract excerpt

The landscape of additional chromosomal alterations (ACAs) and their impact in chronic myeloid leukemia, blast phase (CML-BP) treated with tyrosine kinase inhibitors (TKIs) have not been well studied. Here, we investigated a cohort of 354 CML-BP patients treated with TKIs. We identified +8, an extra Philadelphia chromosome (Ph), 3q26.2 rearrangement, -7 and isochromosome 17q (i(17q)) as the major-route changes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blast Crisis
Share to Bone Marrow
Share to Chromosomes, Human, Pair 3

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fusion Proteins, bcr-abl

Share to Immunophenotyping

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Molecular Targeted Therapy

Share to Translocation, Genetic

Source

Identifiers

PMID: 27560111
DOI: 10.1038/leu.2016.231

Genes

ABL1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cytogenetic landscape and impact in blast phase of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.PMID 27560111Read ↗

Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapySemantic proximity Read ↗

Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia.Semantic proximity Read ↗

High-risk additional chromosomal abnormalities at low blast counts herald death by CMLSemantic proximity Read ↗

Clonal chromosomal abnormalities appearing in Philadelphia chromosome–negative metaphases during CML treatmentSemantic proximity Read ↗

Mutational landscape of chronic myeloid leukemia: more than a single oncogene leukemia.Semantic proximity Read ↗

Accelerated and Blast Phase Myeloproliferative Neoplasms.Semantic proximity Read ↗

Chronic myeloid leukemia with complex karyotypes: Prognosis and therapeutic approachesSemantic proximity Read ↗

Targeted next-generation sequencing in blast phase myeloproliferative neoplasms.Semantic proximity Read ↗

Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysisSemantic proximity Read ↗

Genomic Mechanisms Influencing Outcome in Chronic Myeloid LeukemiaSemantic proximity Read ↗

Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitorsSemantic proximity Read ↗

New Pattern of Emerging Somatic Mutations in Optimal Responders Following Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia PatientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.